First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

© 2025 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

Author Information

Kjetil Berner*,¹,
Eivor Hernes*,²,
Monika Kvassheim³,⁴,
Mona-Elisabeth Revheim²,⁴,⁵,
Julie Bastiansen¹,
Silje Selboe²,
Charlotte L. Bakken¹,
Simen R. Grønningsæter³,⁶,
Øyvind S. Bruland¹,⁴,
Roy H. Larsen⁷,
Lily Bouzelmat⁸,
Vicki L. Jardine⁸ and
Caroline Stokke³,⁶

¹Department of Oncology, Oslo University Hospital, Oslo, Norway;
²Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;
³Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;
⁴Institute of Clinical Medicine, University of Oslo, Oslo, Norway;
⁵Intervention Centre, Oslo University Hospital, Oslo, Norway;
⁶Department of Physics, University of Oslo, Oslo, Norway;
⁷Sciencons AS, Oslo, Norway; and
⁸ARTBIO Limited, London, United Kingdom